REG - GENinCode PLC - Collaboration with US healthcare provider

GenincodeAnnouncement

19/07/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230719:nRSS4139Ga&default-theme=true

RNS Number : 4139G  GENinCode PLC  19 July 2023

GENinCode Plc

("GENinCode" or the "Company")

 

Collaboration with US healthcare provider for CARDIO inCode-Score® testing

MedStar to start clinical use of CARDIO inCode-Score® polygenic testing to
prevent cardiovascular disease

 

Oxford, UK. GENinCode Plc (AIM: GENI), the predictive genetics company focused
on the prevention of cardiovascular disease, announces its collaboration with
MedStar Health ("MedStar"), a ten-hospital health system in the Washington,
D.C. area, to use its CARDIO inCode-Score® ("CIC-SCORE") test in primary care
for the risk assessment of coronary heart disease ("CHD"). Results of the
CIC-SCORE test will be combined with the standard American College of
Cardiology Atherosclerotic Cardiovascular Disease (ASCVD) Risk Calculator to
identify patients who could benefit from earlier preventive treatment.

 

The CIC-SCORE test assesses an individual's polygenic (DNA) risk of CHD which,
together with their clinical risk, provides a comprehensive risk assessment of
CHD. It also addresses the well-recognised need for improvement in CHD
standard of care practices.

 

As the largest healthcare provider in the Mid-Atlantic, MedStar is an
effective incubator for evaluating new clinical applications and through this
study, MedStar physicians will provide valuable feedback on the clinical
utility of CIC-SCORE in the primary care setting. The clinical utility data
generated will support coverage determination and reimbursement for CIC-SCORE
with the Centers for Medicare and Medicaid Services (CMS). William Weintraub,
MD
(https://www.medstarhealth.org/innovation-and-research/medstar-health-research-institute/principal-investigators/william-s-weintraub)
, Director of Population Health Research at MedStar Health Research Institute
and Kristen Miller, PhD
(https://www.medstarhealth.org/innovation-and-research/medstar-health-research-institute/principal-investigators/kristen-e-miller)
, Scientific Director for the National Center for Human Factors in Healthcare
at MedStar Health Research Institute, are co-Primary Investigators and
Christina Schreiber, DO
(https://www.medstarhealth.org/doctors/christina-m-u-schreiber-do) , a family
medicine primary care provider with MedStar, is the physician lead for the
study.

 

The collaboration with MedStar represents the first major US institution to
begin clinically assessing CIC-SCORE, forming part of the Early Access
commercial programme now underway.

 

Clinicians have for many years recognised the importance of prior CHD events
(e.g. heart attack) within families of their patients because genetic factors
contribute to the development of atherosclerosis and a patient's family
history has become a surrogate for their inherited genetic risk. In recent
years, with the advance of genomics, it has become possible to add genetic
profiling to conventional CHD risk factors. The combination of genetics and
conventional clinical risk factors will enhance the predictive capability of a
patient's risk resulting in a more 'personalised' approach to preventive care.

 

The CIC-SCORE test is a patent protected in-vitro diagnostic polygenic test
used to assess the risk of CHD. GENinCode procesess the CIC-SCORE test at its
laboratory in Irvine, California and delivers online reports to physicians via
its proprietary cloud-based 'SITAB' platform.

 

Matthew Walls, CEO of GENinCode Plc said: "We are pleased to announce our
first major US clinical collaboration with MedStar, which will focus on use of
CIC-SCORE to identify patients at high risk of heart disease, the largest
cause of death in the US. We look forward to working closely with the MedStar
team to identify patients at risk, inform personalised treatment and prevent
coronary heart disease."

 

William S. Weintraub Director of Population Health Research MedStar Health
Research Institute and Professor of Medicine at Georgetown University
commented: "We are delighted to collaborate with GENinCode to implement
CIC-SCORE for the prevention of cardiovascular disease. This collaboration
marks a major step in primary care practice for the risk assessment of CHD and
we welcome this approach to help advance our clinical practice and reduce the
onset of cardiovascular disease."

 

For more information visit www.genincode.com (http://www.genincode.com)

Enquiries:

 

 GENinCode Plc                          www.genincode.com (http://www.genincode.com) or via Walbrook PR
 Matthew Walls, CEO

 Stifel Nicolaus Europe Limited (Nomad and Joint Broker)                                       Tel: +44 (0)20 7710 7600
 Alex Price / Ben Maddison / Richard Short

 Cenkos Securities Plc (Joint Broker)   Tel: +44 (0)20 7397 8900
 Giles Balleny / Max Gould
 Dale Bellis / Michael Johnson (Sales)
 Walbrook PR Limited                                                 Tel: 020 7933 8780 or genincode@walbrookpr.com
 Anna Dunphy  / Louis Ashe-Jepson / Phillip Marriage

 

About GENinCode:

GENinCode Plc is a UK based company specialising in genetic risk assessment of
cardiovascular disease. Cardiovascular disease is the leading cause of death
and disability worldwide.

 

GENinCode operates business units in the UK, Europe through GENinCode S.L.U,
and in the United States through GENinCode U.S. Inc.

 

GENinCode predictive technology provides patients and physicians with globally
leading preventative care and treatment strategies. GENinCode CE marked
invitro-diagnostic molecular tests combine clinical-genetic algorithms and
bioinformatics to provide advanced patient risk assessment to predict disease
onset.

 

About MedStar Health:

MedStar Health combines the best aspects of academic medicine, research, and
innovation with a complete spectrum of clinical services to advance patient
care. As the largest healthcare provider in Maryland and the Washington, D.C.,
region, MedStar Health's more than 300 care locations include 10 hospitals, 33
urgent care clinics, ambulatory care centers, and primary and specialty care
providers. MedStar Health is also home to the MedStar Health Research
Institute and a comprehensive scope of health-related organizations all
recognized regionally and nationally for excellence. MedStar Health has one of
the largest graduate medical education programs in the country, training 1,150
medical residents annually, and is the medical education and clinical partner
of Georgetown University. MedStar Health is a $6.7 billion, not-for-profit,
regional healthcare system based in Columbia, Maryland, and one of the largest
employers in the region. MedStar Health's team of more than 31,000 includes
physicians, nurses, and many other clinical and non-clinical associates who
together support MedStar Health's patient-first philosophy that combines care,
compassion, and clinical excellence with an emphasis on customer service.
Visit MedStarResearch.org for more information.

About Cardiovascular Disease (CVD):

GENinCode specializes in polygenic risk assessment of CVD, the leading cause
of death and disability worldwide. CVD is a broad disease classification which
encompasses coronary heart disease ("CHD") (causing angina, heart attack and
heart failure), cerebrovascular disease (causing stroke, and some dementia),
peripheral vascular disease (causing limb ischaemia, and some chronic kidney
disease) and venous thromboembolism. CHD is the most common type of heart
disease in the US and is often referred to as coronary artery disease or
ischemic heart disease. For some people, the first sign of CHD is a heart
attack. CHD is caused by plaque build up in the walls of the arteries that
supply blood to the heart (coronary arteries) and other parts of the
body.

CVD accounts for an estimated 17.9 million deaths globally each year and
accounts for 1 in every 4 deaths in the United States. By 2030 the global cost
of CVD is set to rise from approximately US$863 billion in 2010 to US$1,044
billion and is both a major health issue and global economic burden. More than
four out of five CVD deaths are due to heart attacks and strokes, and one
third of these deaths occur prematurely in people under 70 years of age.

 

The current standard of care for assessing cardiovascular risk is based on
traditional clinical risk factors such as age, sex, smoking, blood pressure
and cholesterol levels from which individuals are categorized as being at low,
borderline, intermediate or high risk of a CHD event. This categorization is
imperfect as CHD events frequently occur in those thought to be at low or
intermediate risk. The size of the populations classified at low through to
intermediate risk are much larger than those at high risk so whilst the
relative risk of a CHD event may be small, the absolute number of CHD events
in low and moderate risk populations is much greater than the number of events
in higher risk categories.

 

The most important behavioural risk factors of heart disease and stroke are
unhealthy diet, physical inactivity, tobacco use and harmful use of alcohol.
The effects of behavioural risk factors may show up in individuals as raised
blood pressure, raised blood glucose, raised blood lipids, overweight and
obesity. These "behavioural risks factors" can be measured in primary care
facilities and indicate an increased risk of heart attack, stroke, heart
failure and other complications. Genetic risk assessment helps to identify
individuals in low or moderate risk populations who are at higher risk of a
CHD event than their traditional clinical risk categorisation would suggest.
This allows earlier in-life preventative measures to be put in place to lower
their future risk.

 

Identifying those at highest risk of CVDs and ensuring they receive
appropriate treatment can prevent premature death. Access to noncommunicable
disease medicines and basic health technologies in all primary health care
facilities is essential to ensure that those in need receive treatment and
counselling.

 

Cardiovascular disease causes a quarter of all deaths in the US and is the
largest cause of premature mortality in deprived areas and is typically the
single biggest area of national health care strategy where lives can be saved.
CVD is largely preventable, through lifestyle changes, education and a
combination of public health strategy for treatment and action on smoking and
tobacco addiction, obesity, tackling alcohol misuse and food reformulation.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCFLFEVDTITLIV